Eli Lilly Devestated That Retatrutide Actually Works

"Everyone, please stop taking gray market retatrutide. You will surely die. (Unless you pay us $1,120 more per month for the same product.)"

On May 21, 2026, Eli Lilly announced an estimated average weight loss of 28.3 percent over 80 weeks at the highest studied dose of its investigational drug retatrutide in TRIUMPH-1. The trial enrolled adults without diabetes who had obesity, or overweight with a weight-related condition. That figure assumed participants remained on treatment without starting prohibited weight-management treatments; the published analysis counting participants regardless of adherence reported 25.0 percent at that dose, versus 3.9 percent with placebo. Either way, it was the sort of number drug developers spend years trying to produce.

In July, the company said it planned to submit its U.S. approval application in the first quarter of 2027.

At the pharmaceutical industry’s Committee on Appropriate Timing, the figures were received with professional concern. There were already people seeking something labeled retatrutide through unauthorized online channels. Some claimed to be losing weight. The committee could not verify what was in their vials, but it had no trouble picturing the commercial difficulty of someone reaching the launch date with less weight to lose.

A representative from the committee's forecasting department introduced a slide titled PATIENTS AT RISK OF IMPROVING PREMATURELY.

"It is one thing for a treatment to work," he said. "It is another for an outcome to occur outside the approved sales window."

The room agreed on a distinction worth making. Retatrutide was not approved. An injection from an unknown online seller was not a clinical-trial product merely because its label used the same name. Verification, manufacturing controls and medical supervision were serious matters. The science adviser emphasized this, and for several minutes the committee appeared to be discussing medicine.

The remaining concern, according to a second slide, was whether everyone would still need it once those concerns had been properly addressed.

The trouble with a successful experiment

Retatrutide is a synthetic peptide, a chain of amino-acid building blocks designed to activate three hormone receptors: GIP, GLP-1 and glucagon. Peptides are not exotic intruders in human biology. The body makes many of them, sending short chemical messages about appetite, blood sugar and countless other tasks. Most do their work without a brand campaign.

This ought to have been reassuring. Instead, it reopened the committee’s oldest problem with nature: its reluctance to explain which department owns the invention.

"There is something extremely dangerous and troubling about everyday people putting their lives at risk by buying Retatrutide directly from the same Chinese vendors that we plan on paying to make our Retatrutide.."

"We believe in innovation," said the director of market protection. "We would merely prefer that it begin in a building that we own."

Eli Lilly itself helped manufacture insulin at scale after joining the University of Toronto project in 1922. That history was filed under Earlier Examples and left off the slide.

Peptide chemistry has long been an established way to make biological molecules. That does not make an injectable drug easy to manufacture well. A sequence can be synthesized in a laboratory and still arrive with the wrong identity, impurities, unstable material or contamination. Producing a reliably tested medicine is different from printing the right chain of letters on a label.

The scientist made this point at some length. She explained that an amino-acid sequence does not certify its own identity, purity, sterility or stability. The committee thanked her for preserving the integrity of the discussion, then moved her comments to Appendix D.

The more interesting commercial question was how something based on amino acids—materials nature had been distributing to bodies without consulting an investor-relations office—could become a valuable proprietary invention.

A lawyer explained that natural phenomena cannot simply be patented as discoveries, citing a Supreme Court decision about naturally occurring DNA. This was not a blanket ban on patents for peptide drugs or for new engineered molecules. Changes to structure, formulation, manufacture and other eligible inventions can make patent protection possible.

"So we can patent the improvements," a vice president asked.

"If they meet the legal requirements."

"And nature?"

"Nature is not available for a licensing conversation."

Nature was assigned to External Contributions, with no further action required.

A lizard who failed to sign the appropriate forms

The history of GLP-1 medicines made the matter worse. Publicly supported research helped establish the hormone’s role in controlling blood sugar. Scientists also identified exendin-4 in the saliva of the Gila monster, a desert lizard that had been managing its metabolism long before the first venture-capital presentation. The peptide activated the GLP-1 receptor and resisted breakdown better than the body’s short-lived GLP-1.

Its synthetic form became exenatide, an early GLP-1 drug. Later medicines used their own engineering strategies to resist breakdown and last longer. The lizard had not invented every subsequent molecule. It had demonstrated that a promising idea could begin outside the industry’s preferred chain of command.

This explanation did not go down well at the patent committee. The lizard, it was noted, had contributed a highly valuable line of research while maintaining neither a legal department nor a LinkedIn account.

"Has anybody approached it about exclusivity?" asked the chair.

The historian said the animal had not been available for comment.

One committee member wanted to know if the lizard could be treated as a former employee. Another felt strongly that its contribution ought to be acknowledged in the scientific literature but not in an earnings call. A third proposed establishing a foundation to preserve its habitat, subject to a broad perpetual license on any additional discoveries made there.

The proposed habitat-and-licensing foundation was referred to a subcommittee for valuation. The lizard continued to be unavailable.

A serious problem in the unauthorized education sector

Meanwhile, the committee turned to TikTok and other places where people were discussing peptides online. The immediate source of embarrassment was not an established clinical outcome from an online vial. It was attention. Consumers had learned a molecule's name, read a few trials and begun talking about it before the formal product launch.

A public-affairs consultant opened a presentation. It listed wellness creators, medical commentators, people posting progress photographs, researchers and entrepreneurs. On one slide was Sean Rakidzich, known for teaching the Airbnb business and now educating peptide-business owners about online marketing. The consultant had highlighted the career change in yellow.

The consultant was troubled by the diversification.

"Airbnb," she said, studying the title. "How did he get from spare bedrooms to amino acids?"

Nobody could explain why the industry should have exclusive rights to a person's second career. This did not prevent a proposal to commission a report.

The report would study whether educational videos were making people less likely to wait politely for all available paperwork. One firm suggested a seven-figure budget for monitoring the spread of publicly available scientific information. A second offered to examine the findings. A third suggested making the videos harder to find while preserving the creators’ right to upload them. It called the service Discovery Friction. A fourth proposed meetings about whether the public was sufficiently informed to be permitted to ask for more information.

The committee endorsed the importance of transparency. The contracts were circulated privately.

The right kind of caution

One point in the discussion required no outside consultant. FDA warnings about unapproved retatrutide products have cited illegal marketing, uncertain product quality and the lack of an approved application. The fact that people in controlled trials lost substantial weight does not prove that anonymous sellers are supplying the same substance, at the advertised strength, without contaminants or unforeseen risks.

The committee accepted this readily. In fact, it accepted the distinction so enthusiastically that an entire communications team was assigned to it. The team was asked to remind the public that "works in a trial" and "safe to buy from an anonymous website" are not equivalent statements. They are not.

A marketing executive asked whether the statement could include a date on which the molecule was expected to become more reassuring.

The scientist declined to help with that version.

The committee then considered the worst-case scenario: a nation of people who had already lost the weight they were expected to pay to lose later. Nobody presented evidence that this was happening at scale. The problem was, therefore, suitable for a forecast. Forecasts allow a large organization to discuss imaginary losses in units of real dollars.

An analyst was asked to model three populations: patients who had not heard of retatrutide; patients who had heard of it but waited; and patients who might enter the launch period with fewer pounds than had been allocated to them in the demand projections.

"Can we make the third group larger?" someone asked.

"That would make the problem worse."

"Yes," the chair said. "But the presentation stronger."

The approved window

By the final session, the committee had accepted that controlled evidence and verified supply matter. It also accepted the practical difficulty of explaining why both matter when the proposed medicine has already produced eye-catching results in the company's own trial reports.

A regulatory liaison suggested plain language: the research is promising; regulatory review is incomplete; unapproved online products can be dangerous. It was accurate, short and hard to improve.

The chair called for revisions anyway.

A consultant returned with a new phrase: Responsible Outcome Sequencing. It meant that the public should regard the same future outcome differently depending on whether it occurred during a controlled trial, after a lawful product launch, or in a hypothetical online success story that nobody could verify.

The scientist pointed out that the third category was not comparable to the other two.

The consultant said this was why the presentation contained three categories.

Outside the meeting, the actual development program continued. Trials would be analyzed. Regulators would review the evidence. Manufacturing and safety questions would need answers. Nobody sensible could conclude that those steps were optional simply because a molecule appeared powerful.

Inside, the committee had one final administrative concern. It asked the analyst to estimate how many future patients would still be available by the projected launch date.

He opened the spreadsheet.

The column was labeled CUSTOMERS, PENDING.

For the first time all day, everyone agreed it was important that nothing move too quickly.

Editor's note: This is satire. The committee, its quotations, budgets, forecasts and creator-monitoring presentation are invented, not allegations about Eli Lilly, FDA or their conduct. The trial results, regulatory status, scientific history and patent-law references are sourced. Online products labeled retatrutide are unapproved, and their identity, quality and safety cannot be inferred from clinical trial results.

Image: AI-generated conceptual illustration of a fictional corporate meeting.